Fludeoxyglucose F-18
FDA-approved product (injectable, injection), marketed as Fludeoxyglucose F18.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 0 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLNo approved indication recorded
ChEMBL records no approved indication for Fludeoxyglucose F-18. Its therapeutic class is shown instead.
- WHO therapeutic group
- Other diagnostic radiopharmaceuticals for tumour detection
- FDA pharmacologic class
- Radioactive Diagnostic Agent FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
No supported pathogen reaches ≥40% AI-predicted activity for Fludeoxyglucose F-18, so it is not among the repurposing candidates. Its predictions are shown below.
AI-predicted activity
AI prediction · nothing measured- MRSA18.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli6.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae21.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis13.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Fludeoxyglucose F-18 with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- TicagrelorExisting use: Acute coronary syndrome, Acute myocardial infarction, Coronary artery disease and 6 more62.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Quinapril HydrochlorideExisting use: Cardiovascular disease, Diabetes mellitus, Heart failure and 3 more62.3% AI-predicted activityagainst M. tuberculosis33 registered studies
- BelzutifanExisting use: Clear cell renal carcinoma, Hemangioblastoma, Neoplasm and 4 more62.2% AI-predicted activityagainst M. tuberculosis45 registered studies
- ChlorprothixeneExisting use: Psychosis62.2% AI-predicted activityagainst M. tuberculosis4 registered studies
- CrizotinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma62.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Pacritinib CitrateExisting use: Neoplasm, Polycythemia vera, Primary myelofibrosis62.2% AI-predicted activityagainst M. tuberculosis2 registered studies
- PralatrexateExisting use: Cancer, Mature T-cell and NK-cell non-Hodgkin lymphoma, Neoplasm and 2 more62.1% AI-predicted activityagainst M. tuberculosis44 registered studies
- Methdilazine HydrochlorideExisting use: Allergic disease62.0% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SirolimusExisting use: Adenoma sebaceum, Angiofibroma, Cancer and 5 more62.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AdagrasibExisting use: Neoplasm, Non-small cell lung carcinoma61.9% AI-predicted activityagainst M. tuberculosis40 registered studies
- TrandolaprilExisting use: Cardiovascular disease, Heart failure, Hypertension and 2 more61.9% AI-predicted activityagainst M. tuberculosis29 registered studies
- Almotriptan MalateExisting use: Migraine disorder61.8% AI-predicted activityagainst M. tuberculosis16 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
PET Imaging to Determine the Role of PET in the Assessment of Regional Disease in Breast Cancer (PET PREDICT Trial)
NCT00201942 · start 2005-02
Registered record
- Registry ID
- NCT00201942
- Conditions
- Breast Cancer
- Interventions
- PET scan
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2005-02
- Completion
- 2007-05
- Enrolment
- 336
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast CancerInterventionPET scanPhasePhase 3Registry statusCompleted2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer
NCT01821105 · start 2004-03
Registered record
- Registry ID
- NCT01821105
- Conditions
- Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV A Bladder Cancer; Stage IV A Rectal Cancer; Stage IV B Colon Cancer; Stage IV B Rectal Cancer
- Interventions
- PET Scan; CT Scan; fludeoxyglucose F 18; computer-aided detection/diagnosis
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2004-03
- Completion
- 2009-11
- Enrolment
- 21
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRecurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV A Bladder Cancer; Stage IV A Rectal Cancer +2 moreInterventionPET Scan; CT Scan; fludeoxyglucose F 18; computer-aided detection/diagnosisPhasePhase 2Registry statusCompletedStem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
NCT00043979 · start 2002-09-19
Registered record
- Registry ID
- NCT00043979
- Conditions
- Sarcoma
- Interventions
- F-18 Fluorodeoxyglucose; therapeutic allogeneic lymphocytes; cyclophosphamide; cyclosporine; doxorubicin hydrochloride; etoposide; fludarabine phosphate; melphalan; prednisone; sirolimus; tacrolimus; vincristine sulfate; peripheral blood stem cell transplantation; Filgrastim; Peripheral Blood Stem Cell donation
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2002-09-19
- Completion
- 2011-12-14
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSarcomaInterventionF-18 Fluorodeoxyglucose; therapeutic allogeneic lymphocytes; cyclophosphamide; cyclosporine +11 morePhasePhase 2Registry statusCompletedPET Scan in Treating Patients With Metastatic Prostate Cancer
NCT00002981 · start 1997-01
Registered record
- Registry ID
- NCT00002981
- Conditions
- Prostate Cancer
- Interventions
- positron emission tomography; fludeoxyglucose F 18; methionine C 11
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 1997-01
- Completion
- 2023-06-12
- Enrolment
- 173
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionpositron emission tomography; fludeoxyglucose F 18; methionine C 11PhaseNot applicableRegistry statusCompletedMetabolic Abnormalities in Children With Epilepsy
NCT00001325 · start 1992-04
Registered record
- Registry ID
- NCT00001325
- Conditions
- Generalized Epilepsy; Infantile Spasms; Metabolic Disease; Partial Epilepsy; Seizures
- Interventions
- 18 FDG
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 1992-04
- Completion
- 2004-06
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGeneralized Epilepsy; Infantile Spasms; Metabolic Disease; Partial Epilepsy +1 moreIntervention18 FDGPhaseNot recordedRegistry statusCompleted